GLP-1 Insurance Denial Statistics 2026How Often Claims Get Rejected — And Why

GLP-1 Insurance Denial Statistics: What Percentage of Claims Get Rejected?

What “Denial” Actually Means (Read This Before You Appeal)

“Denial” is a catch-all word patients use, but insurance datasets count six different things: a pharmacy claim rejection, a prior authorization denial, a formulary exclusion, a benefit exclusion, a step therapy block, and prescription abandonment from cost. They look identical at the pharmacy counter but require completely different responses. Reading the exact wording on your denial letter is the highest-leverage move you can make.

The Denial Taxonomy

Pharmacy claim rejection

The pharmacy tried to bill your insurance and the claim didn't process. Shows up at the counter as "your insurance won't cover this." Triggered by anything from a missing PA to an excluded drug to a wrong NDC code. Often fixable in days.

Prior authorization (PA) denial

Your plan reviewed clinical paperwork and said no. Usually means specific criteria weren't documented (BMI, comorbidity, prior medication trials, lifestyle program participation). Often appealable with better documentation.

Formulary exclusion

The drug isn't on your plan's covered drug list at all. You may be able to request a formulary exception — a formal request asking the plan to cover a non-formulary drug because no alternative is medically appropriate. Harder than a PA, but not impossible.

Benefit exclusion

Your plan document explicitly excludes the category of weight-loss medications. This is a benefit-design choice, not a clinical one. Hardest to overturn unless you have a separate FDA-approved indication that's actually covered (Wegovy's cardiovascular risk reduction indication, Zepbound's OSA indication).

Step therapy

The plan requires you to try and fail other drugs first. Common requirements: Contrave, Saxenda, Orlistat, phentermine, or metformin. Often fixable when you have already tried alternatives or have a documented contraindication.

Abandonment

Technically you got coverage, but the cost was too high to fill the prescription. Not a formal denial, but it functions like one. KFF's Health Tracking Poll found 27% of insured GLP-1 users paid the full cost themselves at some point.

First-Screen Lookup: What Your Letter Says vs. What It Means

How Common Are Denials for Wegovy, Zepbound, Ozempic, and Mounjaro?

Denial rates depend more on what your prescription is for than which drug it is. Weight-loss prescriptions face much higher rejection rates than diabetes prescriptions.

Wegovy (semaglutide 2.4 mg)

Wegovy is FDA-approved for chronic weight management. In March 2024, the FDA also approved Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and overweight or obesity. That second indication can change the coverage analysis — a plan that excludes weight-loss drugs may evaluate Wegovy differently when prescribed for the cardiovascular-risk indication. FDA approval does not guarantee plan coverage, but it creates a different basis for a PA submission.

In July 2025, CVS Caremark moved Wegovy to preferred status on its Standard Control, Advanced Control, and Value commercial template formularies, while removing Zepbound. Most major commercial insurers cover Wegovy with prior authorization when the patient meets BMI thresholds (typically BMI ≥30 with a comorbidity or BMI ≥27 with cardiovascular disease) and has tried and failed lifestyle interventions. No major insurer publishes its Wegovy-specific denial rate.

Zepbound (tirzepatide)

Zepbound has had a rougher coverage year. ICER's 2025 Launch Price and Access Report found that 62% of new commercial Zepbound claims were rejected in Q1 2025 — 43% from insurance noncoverage, 15% from PA or step therapy, and 4% from other reasons. Only 34% were filled as covered, and 4% were abandoned after coverage.

The CVS Caremark formulary move in July 2025 dropped Zepbound from preferred status on Caremark's template formularies in favor of Wegovy. Zepbound also has a second FDA indication: in December 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity. If you have a documented OSA diagnosis, Zepbound prescribed for sleep apnea may go through a different coverage review — including under standard Medicare Part D rather than the new Medicare Bridge.

Ozempic and Mounjaro (off-label denial pattern)

Ozempic and Mounjaro are FDA-approved for type 2 diabetes, not weight loss. When prescribed off-label for weight loss — which is common — coverage outcomes get tricky:

• For type 2 diabetes: generally covered more consistently, though plans can still require prior authorization, step therapy, and diagnosis documentation.
• For weight loss without diabetes: most commercial plans deny because the prescription doesn't match the drug's FDA-approved indication. Medicare Part D won't cover off-label weight-loss use of Ozempic at all.

Foundayo (orforglipron)

The FDA approved Foundayo on April 1, 2026 for chronic weight management. Commercial coverage data is still thin — the drug is only weeks into market. Foundayo was added to the Medicare GLP-1 Bridge drug list on April 6, 2026.

Saxenda and Older GLP-1s

Saxenda (liraglutide) is the older daily-injection GLP-1 still on many plans' step-therapy lists. Some plans require you to try and fail Saxenda before covering Wegovy or Zepbound. If you're being told to “step through” Saxenda, that's why.

The 5 Reasons Most GLP-1 Denials Happen

Most GLP-1 denials in 2026 fall into five repeat patterns. Each needs a different response — the fix matters more than the appeal letter itself.

Verified Denial-Share Matrix

We deliberately don't publish made-up percentages for the bottom three categories. No public dataset breaks them out separately for GLP-1s. Several competing pages do invent these numbers — be skeptical when you see them.

How GLP-1 Denial Statistics Change by Insurance Type

Your denial odds depend heavily on which kind of insurance you have. A single national denial rate is misleading without that context.

Employer-Sponsored Commercial Plans

• ·19% of firms with 200+ workers cover GLP-1s primarily for weight loss in 2025 (KFF)
• ·43% of firms with 5,000+ workers cover GLP-1s for weight loss — up from 28% in 2024 (KFF)
• ·34% of firms with 200+ workers that cover GLP-1s for weight loss require participation in a lifestyle, dietitian, or weight-loss program (KFF). Skipping this requirement is a common denial trigger.
• ·About 12 million people lost commercial Wegovy coverage between 2025 and 2026, and another 12 million lost Zepbound coverage (GoodRx via NPR, April 2026)

ACA Marketplace Plans (HealthCare.gov)

These numbers are not GLP-1-specific — general ACA Marketplace context only.

• ·ACA Marketplace plans denied 19% of in-network claims and 37% of out-of-network claims in 2024 (KFF)
• ·Fewer than 1% of denied claims were appealed (KFF) — the system depends on patients giving up
• ·Of appeals filed, insurers upheld 66% of their original denials (KFF)

Medicaid

Medicaid is the most volatile category in 2026. Coverage depends on your state, the indication on your prescription, and whether you're in fee-for-service or managed-care Medicaid.

Medicare Part D and the New Medicare GLP-1 Bridge

For decades, Medicare Part D generally could not cover drugs used solely for weight loss. That changes — partially — on July 1, 2026.

Medicare Advantage

General Medicare Advantage PA context — not GLP-1-specific:

• ·MA insurers made nearly 53 million PA determinations in 2024 (KFF)
• ·7.7% of PA requests were denied; 11.5% of denied PA requests were appealed
• ·80.7% of appealed denials were overturned — but this is all drugs, not GLP-1s specifically (KFF)

Insurance-Type Quick Reference

Are GLP-1 Denials Worse for Weight Loss Than Diabetes?

Yes. The clearest single dataset is the Endocrine Society's pediatric study of 599 patients, which found GLP-1 prescriptions were denied for 64% of patients with obesity but only 32% of patients with type 2 diabetes. Adult coverage follows the same pattern. The mechanism generalizes; pediatric percentages should not be applied directly to adults.

Why Obesity Coverage Is Treated Differently

1. 1.Legacy benefit design. Many plans still classify weight-loss drugs alongside cosmetic treatments — a holdover from a generation when “diet pills” carried serious safety concerns.
2. 2.Cost projections at scale. An estimated 110 million U.S. adults meet medical eligibility criteria for GLP-1 weight-loss therapy. Even at negotiated prices, that's a budget-shaking population.
3. 3.Adherence concerns. Insurers cite data showing many patients stop GLP-1 therapy within a year. Patient advocates note that low adherence is partly caused by coverage instability.

Cardiovascular and OSA Indications Change the Picture

• →Wegovy for cardiovascular risk reduction (March 2024) — for adults with cardiovascular disease and overweight or obesity. A plan that excludes weight-loss drugs may evaluate Wegovy differently under this indication.
• →Zepbound for moderate-to-severe obstructive sleep apnea (December 2024) — for adults with obesity. A prescription written for sleep apnea goes through a different coverage review.

A new FDA indication doesn't automatically trigger plan coverage — plans update formularies on their own schedules. But it changes the basis for a PA submission and an appeal.

Do GLP-1 Appeals Actually Work?

What We Do Know

• ·KFF's 2024 ACA Marketplace analysis: fewer than 1% of denied claims were appealed. The system depends on patients giving up.
• ·KFF consumer research: 40% of insured adults know they have a legal right to appeal to a government agency or independent medical expert; 51% are not sure; 9% incorrectly believe they don't have that right.
• ·Medicare Advantage data: 80.7% of appealed PA denials are overturned across all drugs (KFF). Proves appeals can work in the broader system — does not prove they work at that rate for GLP-1s specifically.

What Actually Moves the Needle

1. 1.The denial is procedural, not categorical. A PA denied for missing BMI documentation flips much faster than a blanket benefit exclusion.
2. 2.The Letter of Medical Necessity matches the plan's exact criteria. Generic medical-necessity letters fail at higher rates than letters that quote the plan's stated PA criteria and document each one.
3. 3.The clinical record supports the claim: current BMI in chart, comorbidity ICD-10 codes, prior medication trials with dates and outcomes, weight trajectory.
4. 4.Peer-to-peer review is on the table. A direct call between your prescriber and the insurer's medical director is one tool among several — ask whether your insurer offers it.
5. 5.The appeal is filed within deadline. Most plans give 180 days from the denial notice for an internal appeal under federal ACA rules.

Appeal Timelines (Federal Minimums)

These are federal minimums under the ACA. Self-funded ERISA plans can have plan-specific procedures, and some employer-sponsored plans require two internal appeals before external review — check your denial notice and Summary Plan Description.

If You've Been Denied: The 2026 Decision Tree

Step 6: Alternative Pathways While You Appeal

All prices verified May 7, 2026. Re-verify before relying.

What's Missing From the Public Denial Data

No public source reports a clean, real-time denial rate for every GLP-1 by insurer, state, plan, indication, and appeal outcome. Anyone giving you one tidy “GLP-1 denial rate” is averaging across incompatible data or making it up. We chose to label every number on this page by what it counts and what it doesn't.

Specific Gaps in the Public Data

• —By-insurer GLP-1 denial rates — no insurer publishes its GLP-1 denial rate; the only window is anecdotal
• —By-employer denial rates for self-funded plans (which cover 67% of insured workers)
• —Maintenance/continuation denial rates — how often plans deny patients who are already on the drug
• —Appeal outcomes specific to GLP-1s — available appeal data is multi-drug
• —Real-world Medicare Bridge approval rates — the program hasn't launched yet (July 1, 2026)
• —Medicaid managed-care plan-level variation within covering states
• —Patient-level abandonment patterns for compounded and direct-to-consumer pathways

What We Actually Verified

Frequently Asked Questions

What percentage of GLP-1 prescriptions are denied?

The most cited figure is 62.4% of weight-loss GLP-1 pharmacy claims were rejected between January 2021 and October 2024 (AJMC / ICON / Symphony Health). The trend was downward — 74% rejection in 2021 dropping to 60.5% by October 2024. A separate ICER Q1 2025 study found 62% of new commercial Zepbound prescriptions were rejected on first claim. Diabetes-indicated GLP-1s have lower rejection rates because they're standard chronic-disease therapy on most plans.

Is the 62% denial rate for every drug and every plan?

No. The 62.4% figure is a U.S.-wide average across all weight-loss GLP-1s and all payer types from 2021 to 2024. Your personal odds depend on the drug, the indication, your plan type, your state, and whether your plan covers anti-obesity medications at all. Diabetes prescriptions for the same active ingredients have lower denial rates.

Why was Wegovy denied by my insurance?

Common reasons: your plan has a benefit exclusion for weight-loss medications, your plan requires step therapy through a cheaper or older drug first, your prior authorization was missing required documentation (BMI, comorbidities, prior trials), your BMI doesn't meet the plan's threshold, or your formulary doesn't cover Wegovy specifically. Read the exact wording on your denial letter — it changes which next move actually works.

Why was Zepbound denied?

In addition to the standard reasons, Zepbound has been hit specifically by formulary changes. CVS Caremark moved Wegovy to preferred status and removed Zepbound from its Standard Control, Advanced Control, and Value template formularies in July 2025. If your pharmacy benefit uses one of those Caremark templates, your Zepbound denial is likely a formulary issue — and your plan may approve Wegovy instead. Custom employer formularies can have different rules. Zepbound also has an FDA approval for obstructive sleep apnea (December 2024), which can open a different coverage lane if you have a documented OSA diagnosis.

Why was Ozempic denied if my doctor prescribed it for weight loss?

Ozempic is FDA-approved for type 2 diabetes, not weight loss. When prescribed off-label for weight loss, most commercial plans deny because the prescription doesn't match the drug's covered indication. Medicare Part D won't cover off-label weight-loss use of Ozempic at all. If you have type 2 diabetes, your prescriber may use that diagnosis. Prediabetes alone is not the same as type 2 diabetes and may not support Ozempic coverage outside narrow plan-specific criteria. Don't ask anyone to falsify a diagnosis.

Are GLP-1s covered by Medicare?

Starting July 1, 2026, eligible Medicare Part D enrollees can access Wegovy, Zepbound (KwikPen formulation), and Foundayo for $50 per month through the Medicare GLP-1 Bridge. Eligibility requires age 18+, attestation that the drug is prescribed for weight reduction with lifestyle modification, and one of three BMI/condition tiers: BMI ≥35; BMI ≥30 with HFpEF, uncontrolled hypertension on 2+ meds, or CKD stage 3a+; or BMI ≥27 with prediabetes, prior MI, prior stroke, or symptomatic PAD. The program runs through December 31, 2027. The $50 copay doesn't count toward your Part D deductible or the $2,100 out-of-pocket cap, and Medicare Extra Help can't be applied.

Are GLP-1s covered by Medicaid?

It depends on your state. As of January 2026, 13 state Medicaid programs cover GLP-1s for obesity treatment under fee-for-service (KFF). Four states ended coverage on January 1, 2026: California, New Hampshire, Pennsylvania (adults 21+), and South Carolina. North Carolina dropped coverage in October 2025 over a budget stalemate, then reinstated it in December. Coverage for diabetes is much more widely available. Verify with your state Medicaid agency before relying on any list — the policy is unusually volatile.

Do GLP-1 appeals actually work?

Sometimes. Appeals on prior authorization denials, step therapy, and documentation problems frequently succeed when the appeal is properly built. Appeals on outright benefit exclusions usually don't, unless you can reframe the prescription around a separately FDA-approved indication your plan covers. No source publishes a verified GLP-1-specific appeal success rate, so be skeptical of any site that claims one. The '80.7% overturn' rate sometimes cited is from KFF's Medicare Advantage data covering all drugs, not GLP-1s.

How long does a GLP-1 appeal take?

Internal appeals on commercial plans must be decided within 30 days for services not yet received and 60 days for services already received under federal ACA rules. Urgent appeals must be decided within 72 hours. External (independent third-party) review must be decided within 45 days standard or 72 hours expedited. Self-funded ERISA plans can have plan-specific procedures — check your Summary Plan Description.

What's the difference between prior authorization and a benefit exclusion?

A prior authorization denial means your plan covers the drug in principle but needs proof you meet the clinical criteria. It's often fixable with better documentation. A benefit exclusion means your plan doesn't cover that category of medication at all (e.g., 'weight-loss drugs are excluded'). Benefit exclusions are much harder to overturn — your route is usually to find a separately FDA-approved indication your plan does cover, or shift to cash-pay.

Can my insurance stop covering GLP-1s after I already started?

Yes. About 12 million people lost commercial coverage for Wegovy and 12 million for Zepbound between 2025 and 2026 (GoodRx via NPR). Plans change formularies annually or mid-year. Your existing therapy doesn't lock in coverage; the formulary in effect on the date your prescription is filled does. If you get a notice that coverage is changing, ask about formulary exception rights, covered alternatives, and transition supply — most plans must provide a 30–90 day transition fill while you switch.

Is compounded semaglutide covered by insurance?

Almost never. Compounded GLP-1s are not FDA-approved finished drug products and are typically not covered by commercial plans, Medicare, or Medicaid. The FDA states compounded drugs are not reviewed for safety, effectiveness, or quality before marketing and should generally be used only when a patient's medical need cannot be met by an FDA-approved drug. Talk to your prescriber about the safety considerations specific to your situation before pursuing this route.

What should I ask my insurer after a GLP-1 denial?

Six questions: (1) What is the exact reason for the denial? (Get the specific code or category.) (2) What clinical criteria did you use? (Request the plan's PA policy in writing.) (3) Is this a prior authorization denial, formulary exclusion, or benefit exclusion? (4) Can I request a formulary exception or step-therapy exception? (5) What is the deadline for an internal appeal? (6) Do you offer peer-to-peer review between my prescriber and your medical director?

How We Update This Page

This page covers a fast-moving area of health policy. We update on the following cadence:

Sources Cited on This Page

• —AJMC / ICON / Symphony Health, “Yearly Trends in Coverage Rates for GLP-1 RAs in Weight Loss” (claims period Jan 2021 – Oct 2024)
• —ICER, 2025 Launch Price and Access Report
• —KFF, Employer Health Benefits Survey, 2025
• —KFF, Medicaid Coverage of and Spending on GLP-1s, January 2026
• —KFF, Claims Denials and Appeals in ACA Marketplace Plans in 2024
• —KFF, Medicare Advantage Insurers Made Nearly 53 Million Prior Authorization Determinations in 2024
• —KFF Survey of Consumer Experiences with Health Insurance
• —KFF, Health Tracking Poll on GLP-1 affordability
• —CMS, Medicare GLP-1 Bridge program FAQ
• —CMS, Innovation Center BALANCE Model documentation
• —CMS, Interoperability and Prior Authorization Final Rule (CMS-0057-F) fact sheet
• —FDA, Wegovy cardiovascular indication press release, March 2024
• —FDA, Zepbound obstructive sleep apnea indication press release, December 2024
• —FDA, Foundayo (orforglipron) approval, April 1, 2026
• —FDA, Concerns About Unapproved GLP-1 Drugs Used for Weight Loss
• —HealthCare.gov, Internal and External Appeals
• —DOL, Filing a Claim for Your Health Benefits
• —Endocrine Society, ENDO 2024 pediatric GLP-1 study
• —Penn LDI summary of JAMA research on Medicare Part D prior authorization
• —GoodRx, GIP/GLP-1 commercial coverage tracking, 2026
• —NPR, “Patients struggle to pay for obesity drugs as insurance coverage slips,” April 2026
• —AP News, North Carolina State Health Plan GLP-1 coverage decision
• —NCSL, GLP-1s: Cost, Coverage and State Policy Trends
• —CVS Caremark, GLP-1 formulary update (July 2025)
• —NovoCare.com, Wegovy and Ozempic self-pay pricing
• —Lilly.com, Zepbound Self Pay Journey Program
• —California DHCS Medi-Cal Rx, GLP-1 Changes notice (effective Jan 1, 2026)